118 related articles for article (PubMed ID: 9533108)
1. Induction of tirilazad clearance by phenytoin.
Fleishaker JC; Pearson LK; Peters GR
Biopharm Drug Dispos; 1998 Mar; 19(2):91-6. PubMed ID: 9533108
[TBL] [Abstract][Full Text] [Related]
2. Gender does not affect the degree of induction of tirilazad clearance by phenobarbital.
Fleishaker JC; Pearson LK; Peters GR
Eur J Clin Pharmacol; 1996; 50(1-2):139-45. PubMed ID: 8739825
[TBL] [Abstract][Full Text] [Related]
3. The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers.
Fleishaker JC; Hulst LK; Peters GR
Clin Pharmacol Ther; 1994 Oct; 56(4):389-97. PubMed ID: 7955800
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of tirilazad: effects of weight, gender, concomitant phenytoin, and subarachnoid hemorrhage.
Fleishaker JC; Fiedler-Kelly J; Grasela TH
Pharm Res; 1999 Apr; 16(4):575-83. PubMed ID: 10227715
[TBL] [Abstract][Full Text] [Related]
5. Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability.
Fleishaker JC; Pearson PG; Wienkers LC; Pearson LK; Peters GR
J Pharmacol Exp Ther; 1996 May; 277(2):991-8. PubMed ID: 8627582
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of tirilazad in healthy male subjects at doses above 6 mg/kg/day.
Fleishaker JC; Peters GR
Int J Clin Pharmacol Ther; 1997 Jan; 35(1):28-32. PubMed ID: 9021439
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacokinetics of tirilazad mesylate in healthy volunteers and stable subjects with mild liver cirrhosis.
Pearson LK; Fleishaker JC; Peters GR
Eur J Clin Pharmacol; 1996; 50(4):299-304. PubMed ID: 8803523
[TBL] [Abstract][Full Text] [Related]
8. Multiple-dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg/kg/day administered over 5-10 days in healthy volunteers.
Fleishaker JC; Hulst LK; Peters GR
Int J Clin Pharmacol Ther; 1994 May; 32(5):223-30. PubMed ID: 7921515
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adults.
Fleishaker JC; Straw RN; Cross CJ
J Pharm Sci; 1997 Apr; 86(4):434-7. PubMed ID: 9109044
[TBL] [Abstract][Full Text] [Related]
10. Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A.
Fleishaker JC; Pearson LK; Pearson PG; Wienkers LC; Hopkins NK; Peters GR
J Clin Pharmacol; 1999 Mar; 39(3):260-7. PubMed ID: 10073325
[TBL] [Abstract][Full Text] [Related]
11. Effect of age and gender on tirilazad pharmacokinetics in humans.
Hulst LK; Fleishaker JC; Peters GR; Harry JD; Wright DM; Ward P
Clin Pharmacol Ther; 1994 Apr; 55(4):378-84. PubMed ID: 8162663
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: I. Single-dose administration.
Fleishaker JC; Peters GR; Cathcart KS
J Clin Pharmacol; 1993 Feb; 33(2):175-81. PubMed ID: 8382708
[TBL] [Abstract][Full Text] [Related]
13. Lack of a pharmacokinetic/pharmacodynamic interaction between nimodipine and tirilazad mesylate in healthy volunteers.
Fleishaker JC; Hulst LK; Peters GR
J Clin Pharmacol; 1994 Aug; 34(8):837-41. PubMed ID: 7962672
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of tirilazad and U-89678 in ischemic stroke patients receiving a loading regimen and maintenance regimen of 10 mg/kg/day of tirilazad.
Fleishaker JC; Peters GR
J Clin Pharmacol; 1996 Sep; 36(9):809-13. PubMed ID: 8889901
[TBL] [Abstract][Full Text] [Related]
15. Biotransformation of tirilazad in human: 4. effect of finasteride on tirilazad clearance and reduced metabolite formation.
Fleishaker JC; Pearson PG; Wienkers LC; Pearson LK; Moore TA; Peters GR
J Pharmacol Exp Ther; 1998 Nov; 287(2):591-7. PubMed ID: 9808685
[TBL] [Abstract][Full Text] [Related]
16. Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes.
Wienkers LC; Steenwyk RC; Sanders PE; Pearson PG
J Pharmacol Exp Ther; 1996 May; 277(2):982-90. PubMed ID: 8627581
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: II. Multiple-dose administration.
Fleishaker JC; Peters GR; Cathcart KS; Steenwyk RC
J Clin Pharmacol; 1993 Feb; 33(2):182-90. PubMed ID: 8440768
[TBL] [Abstract][Full Text] [Related]
18. Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans--a putative measure of CYP3A induction.
Fleishaker JC; Pearson LK; Peters GR
J Pharm Sci; 1995 Mar; 84(3):292-4. PubMed ID: 7616365
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America.
Haley EC; Kassell NF; Apperson-Hansen C; Maile MH; Alves WM
J Neurosurg; 1997 Mar; 86(3):467-74. PubMed ID: 9046304
[TBL] [Abstract][Full Text] [Related]
20. Biotransformation of tirilazad in human: 3. tirilazad A-ring reduction by human liver microsomal 5alpha-reductase type 1 and type 2.
Wienkers LC; Steenwyk RC; Hauer MJ; Fleishaker JC; Pearson PG
J Pharmacol Exp Ther; 1998 Nov; 287(2):583-90. PubMed ID: 9808684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
